Oral Azacitidine in Transplant-Eligible Patients With Acute Myeloid Leukemia (AML) Suffering From Health-Inequality

This study is testing an oral medication called azacitidine as a "maintenance" treatment for people with acute myeloid leukemia (AML) who are eligible for a bone marrow transplant but face health or access barriers to receiving one. The goal is to help keep the cancer in remission without an immediate transplant. **You may be eligible if...** - You have been diagnosed with AML (not the APL subtype, and FLT3-negative) - You have completed standard induction and consolidation chemotherapy and are in remission - Your doctor considers you eligible for a bone marrow transplant but you are experiencing health inequality barriers - You are able to take oral medication **You may NOT be eligible if...** - Your AML is the APL subtype or FLT3-positive - You are not in remission after chemotherapy - You have significant organ dysfunction that would make treatment unsafe Talk to your doctor to see if this trial is right for you.